July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Visual Outcomes Of Patients With Center-Involving Diabetic Macular Edema And Good Vision
Author Affiliations & Notes
  • Roomasa Channa
    Ophthalmology, Baylor College of Medicine, Houston , Texas, United States
    Wilmer Eye Institute, Maryland, United States
  • Sidra ZAFAR
    Wilmer Eye Institute, Maryland, United States
  • Christina Y Weng
    Ophthalmology, Baylor College of Medicine, Houston , Texas, United States
  • Michael V Boland
    Wilmer Eye Institute, Maryland, United States
  • Footnotes
    Commercial Relationships   Roomasa Channa, None; Sidra ZAFAR, None; Christina Weng, Alcon (C), Alimera Sciences (C), Allergan (C); Michael Boland, Heidelberg (C)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2640. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Roomasa Channa, Sidra ZAFAR, Christina Y Weng, Michael V Boland; Visual Outcomes Of Patients With Center-Involving Diabetic Macular Edema And Good Vision. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2640.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Limited data are available to guide clinicians regarding management of patients with center-involving diabetic macular edema (ci-DME) and Snellen visual acuity (VA) of 20/30 or better. We aimed to describe the clinical course of these patients.

Methods : Retrospective study conducted at the Johns Hopkins Hospital, Wilmer Eye Institute. Patients were included if: 1) aged ≥18 years with a diagnosis of type 2 diabetes 2) seen between July 2013 and May 2018 3) spectral domain optical coherence tomography (SD-OCT) imaging done either on or after the date of diagnosis of DME, 4) visual acuity (VA) of 20/30 or better in ≥ 1 eye and 5) follow-up duration equal to ≥ 3 clinic visits. Patients were identified using billing codes for DME. SD-OCT scans were reviewed to confirm ci-DME. Ci-DME was defined as retinal thickening ≥305 microns for females and ≥320 microns for males within central 1mm of the ETDRS grid or presence of cysts due to DM. One eye of each patient was randomly selected for analysis.

Results : 121 patients (121 eyes) with ci-DME met the inclusion criteria. Mean patient age was 63.8 ±10.9 years. Mean (SD) central 1mm thickness and VA at baseline were 316.5 (±63.2) µm and 0.1 (±0.1) logMAR [Snellen Equivalent (SE) 20/25], 60% were phakic. Mean duration of follow-up was 1.8 (±0.7) years. Mean logMAR VA at final follow-up visit was 0.2 (±0.2) logMAR [SE 20/32]. 67 eyes (55.4%) underwent treatment: 66 received anti-VEGF injections and 1 received focal laser. Mean number of injections performed was 6.4 (±4.6), 2.8 injections/year. Baseline and final VA was comparable between the 2 groups that underwent treatment versus those that did not at 0.1 (±0.1) logMAR (p=0.9) and 0.2 (±0.0) logMAR (p=0.7), respectively. Mean change in VA in both groups was +0.1 logMAR at the end of follow-up (p=0.8).

Conclusions : After an average of 2 years of follow-up there was no statistically significant difference in final visual acuity or retinal thickness irrespective of whether patients received or did not receive treatment with anti-VEGF agents.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×